1-3 of 3
Hans B. Ommen, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

qPCR MRD Monitoring in Peripheral Blood May Predict Hematological Relapse in Pediatric Acute Myeloid Leukemia

Kristian L Juul-Dam, MD, Charlotte G Nyvold, PhD, Hans B Ommen, MD PhD, Olafur G Jonsson, MD, Birgitte Lausen, MD, Kirsi Jahnukainen, MD PhD, Henrik Hasle, MD
Journal: Blood
Blood (2015) 126 (23): 3749.
https://doi.org/10.1182/blood.V126.23.3749.3749
Published: 2015
Journal Articles

Relapse Prediction in AML Patients in Complete Remission Using WT1 as a Molecular Marker: Development of a Mathematical Model To Predict Time from Molecular to Clinical Relapse and Define Optimal Sampling Intervals.

Hans B. Ommen, MD, Charlotte G. Nyvold, PhD, Karin Brændstrup, Bodil L. Andersen, Ingrid B. Ommen, MSc, Henrik Hasle, PhD, Peter Hokland, DMSc, Mette Ostergaard, PhD
Journal: Blood
Blood (2007) 110 (11): 3495.
https://doi.org/10.1182/blood.V110.11.3495.3495
Published: 2007
Journal Articles

Loss of Heterozygosity (LOH) of the NUP98 Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML).

Magdalena Plasilova, MD, PhD, Hans B. Ommen, MD, Jaroslav Jelinek, MD, PhD, Jean-Pierre Issa, MD, Elyn R. Riedel, Phd, Susan Mathew, PhD, Amy Chadburn, MD, Pengbo Zhou, PhD, Peter Hokland, MD, Malcolm A.S. Moore, PhD
Journal: Blood
Blood (2006) 108 (11): 2356.
https://doi.org/10.1182/blood.V108.11.2356.2356
Published: 2006